<DOC>
	<DOCNO>NCT00500227</DOCNO>
	<brief_summary>The objective study evaluate , acromegalic patient disease persistence surgery treat somatostatin analogue , histopathological , clinical , morphological biochemical factor predictive hormonal control .</brief_summary>
	<brief_title>Predictive Factors Response Somatostatin Analogues Acromegalic Patients With Persistent Disease Following Surgery</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Acromegalic patient persistent disease ( growth hormone â‰¥ 1ng/ml follow oral glucose tolerance test and/or insulin like growth factor 1 normal range sex age ) 3 6 month transsphenoidal transfrontal surgery Patients contribute enough material tumour histopathological study Patients receive radiation therapy receive observational study period Patients treat , treatment anticipate , either dopaminergic agonist growth hormone receptor antagonist Patients history hypersensitivity somatostatin analogue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>